A. David Paltiel, MBA, PhD
Professor of Public Health (Health Policy), Professor of Management, and Professor in the Institution for Social and Policy StudiesCards
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Contact Info
Health Policy & Management
60 College Street
New Haven, CT 06510
United States
About
Titles
Professor of Public Health (Health Policy), Professor of Management, and Professor in the Institution for Social and Policy Studies
Affiliated Faculty, Yale Institute for Global HealthBiography
The objective that guides Dr. Paltiel's scholarly activities is to promote a reasoned approach to decision making and resource allocation in public health and medicine. Trained in the field of Operations Research, Dr. Paltiel designs and implements policy models and cost-effectiveness analyses. He has a special interest and expertise in HIV/AIDS and has published broadly on the cost-effectiveness of testing, prevention, treatment, and care, both in the United States and around the world.
Appointments
Health Policy & Management
ProfessorPrimary
Other Departments & Organizations
- Global Health Studies
- Health Policy & Management
- IBM Registry
- Public Health Modeling
- Yale Institute for Global Health
- Yale School of Public Health
- Yale Ventures
- Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
- YSPH Global Health Concentration
Education & Training
- PhD
- Yale University, Operations Research (1992)
- MBA
- Yale University (1985)
- BA
- McGill University (1981)
Research
Overview
- Novel approaches to the design and evaluation of combination HIV prevention. The goals of this NIMH-funded grant project are to develop and illustrate three novel ways of thinking about HIV prevention program design and evaluation: viewing HIV prevention in terms of policy bundles; looking beyond program cost-effectiveness to program affordability; and designing financial incentives that translate into better long-term HIV outcomes. The broad objective that guides this research is to squeeze the greatest possible benefit out of every HIV prevention dollar.
- Economic Modeling for HIV, Viral Hepatitis, STD, TB and School Health. The goal of this CDC-funded collaborative grant to the Harvard School of Public Health (Principal Investigator: Joshua Salomon) is to conduct health and economic modeling to inform decision-making on HIV, hepatitis, STD, TB and school health at national, state and local levels, in partnership with the National Center for HIV/AIDS Viral Hepatitis, STD and TB Prevention.
- Cost-Effectiveness of Preventing AIDS Complications (CEPAC-US). The goal of this NIAID-funded collaborative grant to Massachusetts General Hospital (Principal Investigator: Kenneth Freedberg) is to develop a computer simulation model of advanced HIV disease and use to project the costs and consequences of alternative patient care strategies.
- Optimizing HIV Care in Less Developed Countries (CEPAC-International). The goal of this NIAID-funded collaborative grant to Massachusetts General Hospital (Principal Investigator: Kenneth Freedberg) is to provide mentoring for young investigators in patient-oriented HIV research and use ongoing HIV simulation model in conjunction with mentoring efforts to address critical HIV clinical management questions in the US and internationally.
- Making Better Decisions: Policy Modeling for AIDS & Drug Abuse. The goal of this NIDA-funded collaborative grant to Stanford University (Principal Investigator: Douglas Owens) is to develop and apply mathematical policy modeling techniques to the evaluation of AIDS‑related public health interventions.
- Novel Methods to Inform HIV/TB Clinical Trial Development. The goals of this NIAID-funded collaborative grant (Principal Investigator: Rochelle Walensky) are to apply a mathematical simulation modeling framework, based on the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Model, to the NIAID/ACTG clinical trials infrastructure. We propose to inform the development, design, and assessment of therapeutic, diagnostic, and 'strategy' clinical trials in HIV/TB care in international settings. The ultimate goal of this project is to apply novel scientific methods in a highly innovative fashion, to maximize trial investments. It will develop new scientific knowledge of value to HIV/TB investigators, as well as clinical trialists in many areas of medicine.
- Typhoid modeling studies for typhoid conjugate vaccine cost effectiveness and for typhoid delivery strategy. The goals of this project, funded by a grant from the Bill & Melinda Gates Foundation (Principal Investigator: Virginia E. Pitzer), are to conduct research aimed toward the prevention of HIV infection and the reduction of the negative consequences of HIV disease in vulnerable and underserved populations in the U.S.
- A unified intervention for young gay and bisexual men's minority stress, mental health, and HIV risk. The goals of this NIMH-funded grant (Principal Investigator: John Pachankis) are to address key sources of HIV risk among MSM, including stigma-related stress and associated mental health and substance use difficulties, and to use the intervention developed in this project to reduce HIV risk behavior among MSM and therefore the spread of HIV.
- Improving HIV Prevention and Treatment in Ukraine through Innovations in Healthcare Integration for People Who Inject Drugs. The goals of this NIDA-funded grant (Principal Investigator: Frederick L. Altice) are to use a multi-level, implementation science framework and multi-site cluster design to compare Quality of Health Indicator outcomes in PWIDs treated in integrated primary care centers with those who receive standard of care.
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Gregg Gonsalves, PhD
Harlan Krumholz, MD, SM
Kurt Petschke
Lisa Gale Suter, MD
Alexandra Savinkina, MSPH
Jason L. Schwartz, PhD
South Africa
Acquired Immunodeficiency Syndrome
HIV
France
Health Resources
Health Policy
Publications
2024
Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study
Thielking A, Fitzmaurice K, Sewpaul R, Chrysanthopoulou S, Dike L, Levy D, Rigotti N, Siedner M, Wood R, Paltiel A, Freedberg K, Hyle E, Reddy K. Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study. Journal Of The International AIDS Society 2024, 27: e26315. PMID: 38924347, PMCID: PMC11197963, DOI: 10.1002/jia2.26315.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMortality hazard ratioSmoking cessationLife yearsNever smoking statusLife expectancyVirologically suppressed PWHSmoking statusTobacco smokeIntegrate tobacco cessation interventionsMortality riskHazard ratioTobacco cessation interventionsSmoking cessation increasesTobacco-related illnessesImpact of tobacco smokingAntiretroviral therapyMortality risk increaseProportion of deathsChronic respiratory conditionsImpact of smokingCohort of PWHVirological non-suppressionCessation interventionsVirologic suppressionHIV careProjecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee
Borre E, Ahonkhai A, Chi K, Osman A, Thayer K, Person A, Weddle A, Flanagan C, Pettit A, Closs D, Cotton M, Agwu A, Cespedes M, Ciaranello A, Gonsalves G, Hyle E, Paltiel A, Freedberg K, Neilan A. Projecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee. Clinical Infectious Diseases 2024, ciae243. PMID: 38913762, DOI: 10.1093/cid/ciae243.Peer-Reviewed Original ResearchAltmetricConceptsCenters for Disease Control and PreventionIncrease HIV testingHuman immunodeficiency virus testingHuman immunodeficiency virusPriority populationsPrEP provisionCare linkageHIV testingPrevention fundingSurvivors of sex traffickingPregnant peopleTransgender womenLife yearsCondom useHIV prevention fundsUS Centers for Disease Control and PreventionDisease Control and PreventionBaseline condom useControl and PreventionReduced condom useHuman immunodeficiency virus transmissionHeterosexual Black womenPreexposure prophylaxisHIV transmissionBlack womenCost‐Effectiveness of Community‐Based Diet and Exercise for Patients with Knee Osteoarthritis and Obesity or Overweight
Kopp P, Yang C, Yang H, Katz J, Paltiel A, Hunter D, Callahan L, Mihalko S, Newman J, DeVita P, Loeser R, Miller G, Messier S, Losina E. Cost‐Effectiveness of Community‐Based Diet and Exercise for Patients with Knee Osteoarthritis and Obesity or Overweight. Arthritis Care & Research 2024, 76: 1018-1027. PMID: 38450873, DOI: 10.1002/acr.25323.Peer-Reviewed Original ResearchAltmetricConceptsBody mass indexUsual careQuality-adjusted life yearsHealth educationIncremental cost-effectiveness ratioKnee osteoarthritisKnee OAGroup-based health educationWestern Ontario and McMaster Universities Osteoarthritis Index pain scoreLifetime costsOA careE programCost-effectiveIncremental cost-effectivenessFunctional limitationsIncreased lifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioLife yearsMass indexPain reductionSocietal perspectiveCohort characteristicsKneeExerciseComparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccine
2023
Optimizing COVID-19 testing strategies on college campuses: Evaluation of the health and economic costs
Johnson K, Pasco R, Woody S, Lachmann M, Johnson-Leon M, Bhavnani D, Klima J, Paltiel A, Fox S, Meyers L. Optimizing COVID-19 testing strategies on college campuses: Evaluation of the health and economic costs. PLOS Computational Biology 2023, 19: e1011715. PMID: 38134223, PMCID: PMC10773932, DOI: 10.1371/journal.pcbi.1011715.Peer-Reviewed Original ResearchAltmetric965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee
Borre E, Ahonkhai A, Chi K, Osman A, Thayer K, Person A, Weddle A, Flanagan C, Pettit A, Closs D, Cotton M, Agwu A, Cespedes M, Ciaranello A, Gonsalves G, Hyle E, Paltiel A, Freedberg K, Neilan A. 965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee. Open Forum Infectious Diseases 2023, 10: ofad500.2460. PMCID: PMC10678140, DOI: 10.1093/ofid/ofad500.2460.Peer-Reviewed Original ResearchCitationsConceptsHIV testingHIV prevention fundingHIV transmissionDeath avertedTransgender womenPregnant peopleHIV careRisk groupsCondom usePrevention fundingHIV testing ratesPre-exposure prophylaxisHIV testing frequencyPriority risk groupBlack womenHeterosexual Black womenNumber of peoplePrEP provisionVirologic suppressionIncident HIVUndiagnosed HIVHIV deathsPrEP usePotential ClinicalClinical impactDaily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price
Amick A, Eskibozkurt G, Hosek S, Flanagan C, Landovitz R, Jin E, Wilson C, Freedberg K, Weinstein M, Kazemian P, Paltiel A, Ciaranello A, Neilan A. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clinical Infectious Diseases 2023, 78: 402-410. PMID: 37823865, PMCID: PMC10874274, DOI: 10.1093/cid/ciad566.Peer-Reviewed Original ResearchAltmetricConceptsPre-exposure prophylaxisHIV incidenceRisk of HIVOral PrEPAnnual screeningHuman immunodeficiency virus (HIV) pre-exposure prophylaxisOral HIV pre-exposure prophylaxisHIV pre-exposure prophylaxisIncremental cost-effectiveness ratioHIV RNA levelsYoung menCost-effectiveness ratioAnnual HIVHigher discontinuationPrEP retentionAntiretroviral therapyDrug pricesHIV careLow adherenceLifetime horizonNew infectionsHIVIncidencePrEPRNA levelsThe Value-of-Information and Value-of-Implementation from Clinical Trials of Diagnostic Tests for HIV-Associated Tuberculosis: A Modeling Analysis
Pei P, Fitzmaurice K, Le M, Panella C, Jones M, Pandya A, Horsburgh C, Freedberg K, Weinstein M, Paltiel A, Reddy K. The Value-of-Information and Value-of-Implementation from Clinical Trials of Diagnostic Tests for HIV-Associated Tuberculosis: A Modeling Analysis. MDM Policy & Practice 2023, 8: 23814683231198873. PMID: 37743931, PMCID: PMC10517616, DOI: 10.1177/23814683231198873.Peer-Reviewed Original ResearchConceptsIncremental net monetary benefitOptimal decisionsOptimal strategyNet monetary benefitDecision makers' willingnessHealth economic standpointSputum XpertClinical trialsEconomic outcomesHigh VOTMonetary benefitsNew clinical trial evidenceDiagnostic testsHIV-Associated TuberculosisEconomic standpointClinical trial evidenceVOI analysisPublic health decision makingValue of trialsDownstream health outcomesSouth AfricaEvaluation of trialsHealth decision makingWillingnessDecisionsTobacco Smoking, Smoking Cessation, and Life Expectancy Among People With HIV in South Africa
Thielking A, Fitzmaurice K, Sewpaul R, Dike L, Freedberg K, Hyle E, Levy D, Paltiel A, Rigotti N, Siedner M, Reddy K. Tobacco Smoking, Smoking Cessation, and Life Expectancy Among People With HIV in South Africa. 2023, a6737-a6737. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6737.Peer-Reviewed Original ResearchCost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitions
Academic Achievements and Community Involvement
activity Member
Professional OrganizationsStanford UniversityAdjunct Associate, Center for Health Policy / Center for Primary Care & Outcomes ResearchDetails2008 - Presentactivity Committee Member
Professional OrganizationsBocconi UniversityExternal Member, Committee on Appointments and PromotionsDetails2012 - 2018activity Member, Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse
Advisory BoardsNational Academy of MedicineDetails2016 - 2017honor Connecticut Academy of Science and Engineering
Regional AwardDetails02/01/2014United Statesactivity Member
Peer Review Groups and Grant Study SectionsAgence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS)Details2009 - 2014
Links & Media
News
- May 23, 2024
2024 Top Research Awards Announced
- November 07, 2023
Alumni Day highlights data-driven leadership
- May 05, 2023Source: The Boston Globe
COVID global health emergency declared over as CDC director Rochelle Walensky announces her resignation
- April 04, 2023
YSPH statement on nationwide injunction on ACA preventive care mandates
Related Links
Get In Touch
Contacts
Health Policy & Management
60 College Street
New Haven, CT 06510
United States